Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : China Medical System Holdings Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : CMS will be responsible for the development and commercialization of INCB54707 (povorcitinib), a selective oral JAK1 inhibitor, which is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma & chronic spontaneous...
Brand Name : INCB054707
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : China Medical System Holdings Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : INCB54707 (povorcitinib) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for adult patients with prurigo nodularis. A Phase 3 trial is being planned for prurigo nodularis.
Brand Name : INCB054707
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2024
Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : INCB54707 (povorcitinib) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), vitiligo and prurigo nodularis. A Phase 3 study in HS is also ongoing.
Brand Name : INCB054707
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 10, 2023
Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), vitiligo and prurigo nodularis.
Brand Name : INCB054707
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2022
Lead Product(s) : Povorcitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?